BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Patient video chatting with doctor on mobile phone

Doctor On Demand raises $75M in series D

July 8, 2020
By Meg Bryant
Virtual care provider Doctor On Demand has scooped up $75 million in a series D round led by General Atlantic, with participation from existing investors. The funds are earmarked to fuel the company’s growth and expand access to comprehensive telehealth services across the U.S. Combined with earlier financings, the San Francisco-based company has raised nearly $240 million to date.
Read More

Regulatory front for July 8, 2020

July 8, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Luminex, Modern Allergy Management, WHO.
Read More

Regulatory actions for July 8, 2020

July 8, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Balt, Nonin Medical, Saladax Biomedical, Urocam.
Read More

Other news to note for July 8, 2020

July 8, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3M, American Medical Depot, Attomarker, Becton Dickinson, Bia Separations, Biolase, Chugai Pharmaceutical, Cleveland Clinic Florida, Daxor, Decision Diagnostics, Eos Imaging, Guardant Health, Genex India Bioscience, Global Swift Sensor Distribution, Incode, It Technologies, Janssen Biotech, Ocutrx, Paragon Genomics, Philips, Pulmatrix, Qualcomm, Roche, Run:AI, Sensory Cloud, Smiths Detection, Sonde Health, Thermo Fisher Scientific, Ultraviolet Devices.
Read More

Other news to note for July 8, 2020

July 8, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AB Science, Absolute Antibody, Alnylam, Apeiron, Aprea, Atreca, Benitec, Biosig, BSP, Caligor, Clover, CNS, Cue, Cybin, Emergent Biosolutions, Evotec, Karolinska, Gedeon Richter, Horizon Discovery, Hoth, Intelgenx, Kleo, Maxcyte, Nanoviricides, Ology, Ovation, Pharmaceutics, Plex, Q Biomed, Recce, Reflexion Medical, Sunesis, Taiba, Takeda, Telix, TG, Twist, Viralclear, Vivus, Voltron Xencor.
Read More

In the clinic for July 8, 2020

July 8, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abeona, Angion, Athera, Constant, Eikonizo, Invectys, Moderna, Nextcure, Palatin, PTC, Regenxbio, Ridgeback, Vaccinex, Ziopharm.
Read More
Coronavirus and coins

The need for speed: Novavax receives $1.6B in Operation Warp Speed funding

July 7, 2020
By Lee Landenberger
Two more companies, Novavax Inc. and Regeneron Pharmaceuticals Inc., are on the receiving end of U.S. federal government funding to develop and deliver a COVID-19 vaccine in 2021.
Read More

India’s first COVID-19 vaccine to enter human trials

July 7, 2020
By David Ho and Bryan Wong
Bharat Biotech International Ltd. has successfully developed India’s first indigenous vaccine candidate for COVID-19 to enter human trials. Named Covaxin, the vaccine has been cleared by the Drug Controller General of India (DCGI) and Ministry of Health & Family Welfare for phase I and II trials after the company submitted positive preclinical study results regarding safety and immune response.
Read More
Personal protective equipment

Residuals a point of special concern for FDA in N95 mask reprocessing

July 7, 2020
By Mark McCarty
The U.S. FDA held a July 7 webinar to go over a recent guidance on decontamination and bioburden reduction of N95 masks for the COVID-19 pandemic, and one of the take-away messages is that the agency is still quite concerned about the impact of residues left over from those processes, given that some of these residues can be inhaled by the wearer and trigger health problems of their own.
Read More
Product image

COVID-19, BLM push diabetes equity, access issues as experts assess tech use after ADA

July 7, 2020
By Stacy Lawrence
After the recent conclusion of the American Diabetes Association (ADA) Scientific Sessions, virtual diabetes management company Onduo LLC held an event with the ADA and diabetes researchers to discuss how technology can help to bridge that gap to empower more diabetes patients.
Read More
Previous 1 2 … 418 419 420 421 422 423 424 425 426 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing